Tag: Ki

Following the 1986 Chernobyl disaster, regions like Poland distributed potassium iodide (KI) to their populations and subsequently reported no increase in thyroid cancer cases, illustrating its potential to mitigate harm from radioactive iodine exposure. However, it is a common misconception that potassium iodide prevents radiation poisoning entirely, when in fact, its protective role is specific and limited.

An estimated 90% of drug candidates that enter clinical trials ultimately fail [1.8.2]. To improve success rates, researchers rely on key metrics like the half-maximal inhibitory concentration (IC50). So, what is the interpretation of IC50 values, and how does it guide drug discovery?

While potassium iodide (KI) is a critical protective measure during a radiation emergency, the FDA cautions that it is not for everyone. Understanding **who should avoid potassium iodide** is essential for preventing dangerous side effects and ensuring it is used only by those who will benefit most.